Acute paediatric kidney replacement therapies in Europe: demographic results from the EurAKId Registry.

acute kidney injury continuous kidney replacement therapies intermittent haemodialysis kidney replacement therapies peritoneal dialysis

Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402

Informations de publication

Date de publication:
25 03 2022
Historique:
received: 15 05 2021
pubmed: 30 9 2021
medline: 28 4 2022
entrez: 29 9 2021
Statut: ppublish

Résumé

Acute kidney injury (AKI), particularly that requiring dialysis, is a severe complication in hospitalized children that is associated with high morbidity and mortality. A prospective European AKI registry (EurAKId registry, NCT02960867) was created to describe the epidemiology and outcomes of paediatric patients treated with acute dialysis. Children were recruited who were between 0 and 18 years of age and were treated both in and outside the paediatric intensive care unit (PICU) with peritoneal dialysis (PD), haemodialysis (HD) or continuous kidney replacement therapy (CKRT) for AKI or metabolic derangement, fluid overload (FO), sepsis or respiratory distress. Five age groups and 12 categories of primary diseases were defined. Data on 340 patients were analysed, of whom 86% received dialysis for AKI and 14% for reasons other than AKI. Boys accounted for 60% of the patients. Illness severity was greater in children with cardiac and haematologic diseases than those with kidney diseases. Most patients received dialysis in the PICU (84%). The most frequently used dialysis modality was CKRT (64%), followed by PD (14%) and HD (14%). The overall survival rate was 65%. Survival was significantly lower in children with three comorbidities than in children with no comorbidities (41% and 83%; P < 0.001). The EurAKId registry is the first prospective registry considering paediatric acute kidney replacement therapies (KRTs) in both critical and non-critical care settings, focusing on the three dialysis modalities in Europe. The clinical indications for KRT have expanded; our population was characterized by critically ill patients, primarily boys, who frequently received dialysis in the PICU with CKRT.

Sections du résumé

BACKGROUND
Acute kidney injury (AKI), particularly that requiring dialysis, is a severe complication in hospitalized children that is associated with high morbidity and mortality. A prospective European AKI registry (EurAKId registry, NCT02960867) was created to describe the epidemiology and outcomes of paediatric patients treated with acute dialysis.
METHODS
Children were recruited who were between 0 and 18 years of age and were treated both in and outside the paediatric intensive care unit (PICU) with peritoneal dialysis (PD), haemodialysis (HD) or continuous kidney replacement therapy (CKRT) for AKI or metabolic derangement, fluid overload (FO), sepsis or respiratory distress. Five age groups and 12 categories of primary diseases were defined.
RESULTS
Data on 340 patients were analysed, of whom 86% received dialysis for AKI and 14% for reasons other than AKI. Boys accounted for 60% of the patients. Illness severity was greater in children with cardiac and haematologic diseases than those with kidney diseases. Most patients received dialysis in the PICU (84%). The most frequently used dialysis modality was CKRT (64%), followed by PD (14%) and HD (14%). The overall survival rate was 65%. Survival was significantly lower in children with three comorbidities than in children with no comorbidities (41% and 83%; P < 0.001).
CONCLUSIONS
The EurAKId registry is the first prospective registry considering paediatric acute kidney replacement therapies (KRTs) in both critical and non-critical care settings, focusing on the three dialysis modalities in Europe. The clinical indications for KRT have expanded; our population was characterized by critically ill patients, primarily boys, who frequently received dialysis in the PICU with CKRT.

Identifiants

pubmed: 34586417
pii: 6377828
doi: 10.1093/ndt/gfab280
doi:

Banques de données

ClinicalTrials.gov
['NCT02960867']

Types de publication

Clinical Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

770-780

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the ERA.

Auteurs

Isabella Guzzo (I)

Division of Nephrology and Dialysis, Department of Pediatrics, Bambino Gesù Children's Hospital and Research Institute, Rome, Italy.

Lara de Galasso (L)

Division of Nephrology and Dialysis, Department of Pediatrics, Bambino Gesù Children's Hospital and Research Institute, Rome, Italy.

Aysun Karabay Bayazit (AK)

Department of Pediatric Nephrology, Cukurova University Faculty of Medicine, Adana, Turkey.

Dincer Yildizdas (D)

Department of Pediatric Nephrology, Cukurova University Faculty of Medicine, Adana, Turkey.

Claus Peter Schmitt (CP)

Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany.

Wesley Hayes (W)

Department of Pediatric Nephrology, UCL Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Rukshana Shroff (R)

Department of Pediatric Nephrology, UCL Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Augustina Jankauskiene (A)

Clinic of Pediatrics, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.

Ernestas Virsilas (E)

Clinic of Pediatrics, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.

Germana Longo (G)

Pediatric Nephrology, Azienda Ospedaliera-University of Padua, Padua, Italy.

Enrico Vidal (E)

Department of Medicine DAME-Division of Pediatrics, University of Udine, Udine, Italy.

Sevgi Mir (S)

Department of Pediatric Nephrology, Ege University Faculty of Medicine, Izmir, Turkey.

Ipek Kaplan Bulut (IK)

Department of Pediatric Nephrology, Ege University Faculty of Medicine, Izmir, Turkey.

Marcin Tkaczyk (M)

Department of Pediatrics and Immunology, Nephrology Division, Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.

Francesca Mencarelli (F)

Nephrology and Dialysis Unit, Department of Pediatrics, S. Orsola-Malpighi Hospital, Scientific Institute for Research and Healthcare (IRCCS), Bologna, Italy.

Cristina Bertulli (C)

Nephrology and Dialysis Unit, Department of Pediatrics, S. Orsola-Malpighi Hospital, Scientific Institute for Research and Healthcare (IRCCS), Bologna, Italy.

Mrjana Cvetkovic (M)

Department of Nephrology, University Children Hospital, Belgrade, Serbia.

Mirjana Kostic (M)

Department of Nephrology, University Children Hospital, Belgrade, Serbia.

Fabio Paglialonga (F)

Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRRCS Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy.

Giovanni Montini (G)

Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRRCS Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy.

Ebru Yilmaz (E)

Pediatric Nephrology, Dr Behcet Children Research and Education Hospital, Izmir, Turkey.

Ana Teixeira (A)

Pediatric Nephrology, Centro Materno-Infantil do Norte, Porto, Portugal.

Bahriye Atmis (B)

Erzurum Regional Training and Research Hospital, Erzurm, Turkey.

Franz Schaefer (F)

Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH